Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733139 | 1.00 | MEN1 (0.52) | MEN1KMT2AHPGDL3MBTL1CYP1A2 | |
| SCHEMBL5165402 | 0.82 | GAA (0.64) | MEN1KMT2AKDM4EPOLBHTT | |
| SCHEMBL5164806 | 0.81 | MEN1 (0.53) | MEN1KMT2AL3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL5166003 | 0.80 | SMN1; SMN2 (0.60) | L3MBTL1CYP1A2CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL5164811 | 0.80 | GAA (0.55) | MEN1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL5165342 | 0.78 | ALDH1A1 (0.52) | MEN1KMT2AHPGDSMN1; SMN2GAA | |
| SCHEMBL22353139 | 0.78 | TP53 (0.56) | KMT2ACYP1A2CYP2C19SMN1; SMN2POLB | |
| SCHEMBL5165214 | 0.78 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL5165487 | 0.76 | GAA (0.51) | MEN1KMT2AL3MBTL1KDM4EHTT | |
| SCHEMBL28593071 | 0.75 | SMN1; SMN2 (0.50) | L3MBTL1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117214142-A | Application of [2,2' -bipyridine ] -3-amine in detection of zinc ions and method for visually detecting zinc ions | 新疆理工学院 | 2023-12-12 | — | — | CN | claimed |
| CN-117214142-A | Application of [2,2' -bipyridine ] -3-amine in detection of zinc ions and method for visually detecting zinc ions | 新疆理工学院 | 2023-12-12 | — | — | CN | disclosed |
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | MEN1 4371/4885KMT2A 1237/4885HPGD 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.